Aquilo Capital Management Reveals Latest Holdings Report, Showing Significant Portfolio Changes in Q4 2022

Aquilo Capital Management, LLC has filed its latest 13F holdings report, revealing the fund's changes in holdings from Q3 2022 to Q4 2022. The report shows that the fund has made some significant changes to its portfolio, with changes in both the number of shares held and their respective values.

Amongst the fund's top holdings in Q3 2022 was Arrowhead Pharmaceuticals, a company engaged in the development of RNA interference therapeutics. The fund held 1,218,515 shares in the company, which had a value of $40,272,000 at the time. However, in Q4 2022, the fund reduced its holding in Arrowhead Pharmaceuticals to 1,103,515 shares, a decline of 11.1%. The value of the fund's holding in the company also increased to $44,758,000, an increase of 11.1% from Q3 2022.

Another notable change in the fund's portfolio relates to its holdings in the S&P Biotech ETF, for which it had previously purchased puts. The fund maintained its position in the ETF in the same number of shares in both Q3 2022 and Q4 2022, at 500,000 shares. However, the value of the fund's holding in the ETF increased over the period, from $39,660,000 to $41,500,000, representing a gain of 4.6%.

On the other hand, some of the fund's holdings experienced significant declines from Q3 2022 to Q4 2022. Blueprint Medicines, a company focused on developing targeted therapies for cancer and other genetic diseases, saw the fund's holding increase from 524,268 shares in Q3 2022 to 581,768 shares in Q4 2022, representing a 10.95% increase. However, the value of the fund's holding in the company declined sharply from $34,544,000 to $25,487,000, a decline of 26.2%. Similarly, the fund's holdings in Arvinas, Merus, and Regenxbio saw the value of their holdings decline by 22.9%, 26.6%, and 20.4%, respectively.

The fund did make some notable additions to its portfolio during this period as well. One of the most significant changes was the inclusion of Kymera Therapeutics, a biopharmaceutical company focused on the development of small molecule medicines. The fund added 299,165 shares of Kymera Therapeutics during this period, increasing its holding from 330,246 shares to 629,411 shares, representing a significant increase of 118.5%. The value of the fund's holding in the company also increased from $7,189,000 to $15,710,000 over the period.

Another notable addition to the fund's portfolio was Genmab A/S, a biotechnology company focused on the development of antibody therapeutics for cancer and other diseases. The fund added 2,000 shares of Genmab A/S during this period, increasing its holding from 242,848 shares to 244,848 shares, representing an increase of 0.8%. The value of the fund's holding in the company also increased from $7,867,000 to $10,291,000, representing a gain of 30.8%.

In contrast, the fund decreased its holdings in Spero Therapeutics and 4D Molecular Therapeutics to zero, representing a 100% decrease in the number of shares held.

Overall, the fund's Q3-Q4 13F filings reveal that it has made some significant changes to its holdings. Some holdings have experienced significant declines in value, while others have seen gains. Additionally, the fund has added some new positions to its portfolio, such as Kymera Therapeutics and Genmab A/S. It will be interesting to see if these changes continue in the upcoming quarters or if the fund re-establishes positions in some of the companies where it has reduced its holdings.